Marker Therapeutics, Inc.(MRKR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MRKR Marker Therapeutics, Inc.

Closed President's Day 02-13 16:00:00 EST

1.43

-0.01

-0.69%

盘后1.50

+0.07+4.90%

19:56 EST

High1.53	Low1.41	Vol135.07K
Open1.44	D1 Closing1.44	Amplitude8.33%
Mkt Cap23.84M	Tradable Cap20.19M	Total Shares16.67M
T/O197.66K	T/O Rate0.96%	Tradable Shares14.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MRKR","market":"US","secType":"STK","nameCN":"Marker Therapeutics, Inc.","latestPrice":1.43,"timestamp":1771016400000,"preClose":1.44,"halted":0,"volume":135070,"hourTrading":{"tag":"盘后","latestPrice":1.5,"preClose":1.43,"latestTime":"19:56 EST","volume":2959,"amount":4321.6892,"timestamp":1771030570693,"change":0.07,"changeRate":0.048951,"amplitude":0.048951},"delay":0,"changeRate":-0.006944444444444451,"floatShares":14120600,"shares":16673100,"eps":-1.17,"marketStatus":"Closed President's Day","change":-0.01,"latestTime":"02-13 16:00:00 EST","open":1.44,"high":1.53,"low":1.4101,"amount":197663.693669,"amplitude":0.083264,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.17,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.44,"preHourTrading":{"tag":"盘前","latestPrice":1.45,"preClose":1.44,"latestTime":"08:54 EST","volume":162,"amount":234.23200920000002,"timestamp":1770990845677,"change":0.01,"changeRate":0.006944,"amplitude":0.006944},"postHourTrading":{"tag":"盘后","latestPrice":1.5,"preClose":1.43,"latestTime":"19:56 EST","volume":2959,"amount":4321.6892,"timestamp":1771030570693,"change":0.07,"changeRate":0.048951,"amplitude":0.048951},"volumeRatio":0.5229927871940533,"impliedVol":3.5652,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/MRKR/wiki","defaultTab":"wiki","newsList":[{"id":"2610599950","title":"High Growth Tech Stocks In The US February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610599950","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610599950?lang=en_us&edition=fundamental","pubTime":"2026-02-12 01:08","pubTimestamp":1770829713,"startTime":"0","endTime":"0","summary":"As February 2026 begins, the U.S. stock market has seen a robust start with major indices like the Dow Jones Industrial Average and S&P 500 showing significant gains, reflecting positive investor sentiment despite recent economic uncertainties such as government shutdowns and changes in Federal Reserve leadership. In this dynamic environment, identifying high-growth tech stocks requires careful consideration of factors such as innovation potential, adaptability to market shifts, and financial...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/high-growth-tech-stocks-in-the-us-february-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/high-growth-tech-stocks-in-the-us-february-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PLTR","MRKR","IE00BZ9MQY76.HKD","PLT","VRDN","PLYY","BK4009","IE00B894F039.SGD","PLTD","LU1861559042.SGD","BK4547","IE00B19Z9Z06.USD","PLTW","WDAY","CRC","BK4585","PLTA","BK4588","PLTG","MNTN","PCOR","RDDT","PTIR","BK4613","BK4543","BK4139","STOK","BK4023","SNDK","PLTZ","PLTY","IE00B19Z9P08.USD","PLTU","LU1861558580.USD","PLOO"],"gpt_icon":0},{"id":"2606212007","title":"Marker Therapeutics Receives NIH and CPRIT Funding for Pancreatic Cancer Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2606212007","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606212007?lang=en_us&edition=fundamental","pubTime":"2026-01-26 20:01","pubTimestamp":1769428902,"startTime":"0","endTime":"0","summary":"Marker Therapeutics Inc. has received funding from the National Institutes of Health  Small Business Innovation Research  program and the Cancer Prevention and Research Institute of Texas  to support its upcoming pancreatic cancer program. The company plans to initiate a clinical study in the first half of 2026, building on results from a Baylor College of Medicine-led study that utilized Marker’s Multi-Antigen Targeted T cell technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL9q0Whj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","BK4588","SG9999014013.SGD","SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","BK4139","MRKR","LU2210149790.SGD","LU0314104364.USD","BK4112","SG9999014021.USD","IE00BGHQF748.EUR","LU2210150020.SGD"],"gpt_icon":0},{"id":"2601886852","title":"Marker Therapeutics Secures NIH and CPRIT Funding for Pancreatic Cancer Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2601886852","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601886852?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:01","pubTimestamp":1767614501,"startTime":"0","endTime":"0","summary":"Marker Therapeutics Inc. has secured non-dilutive funding from the National Institutes of Health  Small Business Innovation Research  program and the Cancer Prevention and Research Institute of Texas  to support its pancreatic cancer program. This funding will enable the company to proceed with clinical development of its Multi-Antigen Targeted T cell  therapy for pancreatic cancer without impacting its financial runway or ongoing efforts in lymphoma trials. No other beneficiary organizations are mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL9SWbSN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRKR","IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4139","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2583502468","title":"Marker Therapeutics Showcases MAR-T Cell Therapy Advances and MT-601 Clinical Progress in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502468","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583502468?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:43","pubTimestamp":1763131397,"startTime":"0","endTime":"0","summary":"Marker Therapeutics Inc. has released a corporate presentation highlighting developments in its MAR-T cell therapy platform. The company's lead product, MT-601, is designed to target six tumor-specific antigens, offering broad tumor recognition for both blood and solid tumors. The APOLLO Phase 1 clinical trial for MT-601 has shown durable objective response rates in patients with lymphoma who relapsed after anti-CD19 CAR-T cell therapy or for whom CAR-T cell therapy is not an option. MT-601 is currently being studied in dose escalation and expansion cohorts, including disease-specific groups for diffuse large B cell lymphoma . The presentation also notes improvements in manufacturing processes and higher cell potency compared to earlier studies. Marker Therapeutics maintains a strong intellectual property position and has received over $30 million in non-dilutive funding from sources such as the NIH, FDA, and CPRIT. You can access the full presentation through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL6l3VJj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MRKR"],"gpt_icon":0},{"id":"2583350396","title":"Marker Therapeutics Q3 net loss narrows to $2 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2583350396","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583350396?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:10","pubTimestamp":1763122218,"startTime":"0","endTime":"0","summary":"Marker Therapeutics Q3 net loss narrows to $2 mlnOverviewMarker Q3 net loss narrows to $2 mln from $2.3 mln yr/yrMT-601 shows 66% response rate in relapsed NHL patientsCompany raises $10 mln through A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ0GG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MRKR"],"gpt_icon":0},{"id":"2583508260","title":"Marker Therapeutics Q3 EPS USD -0.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508260","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583508260?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:00","pubTimestamp":1763121603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX56A86E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MRKR"],"gpt_icon":0},{"id":"2583508010","title":"Marker Therapeutics Inc: Existing Cash, Cash Equivalents and Restricted Cash Will Fund Operating Expenses Through Q3 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583508010?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:00","pubTimestamp":1763121603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX56A86E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRKR","BK4139"],"gpt_icon":0},{"id":"2581724006","title":"Marker Therapeutics Appoints Kathryn Penkus Corzo to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2581724006","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581724006?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA1BGKDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MRKR"],"gpt_icon":0},{"id":"2581972231","title":"Press Release: Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2581972231","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581972231?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345800,"startTime":"0","endTime":"0","summary":"HOUSTON, Nov. 05, 2025  -- Marker Therapeutics, Inc. , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025.\"I am honored to join Marker's Board of Directors at such a pivotal time for the Company,\" said Ms. Penkus Corzo. \"Marker's Multi-Antigen Recognizing  T cell platform represents a next-generation approach in cell therapy--addressing key limitations of current treatments with the potential to offer improved clinical outcomes to patients with limited therapeutic options. I am inspired by the team's scientific rigor and commitment to patients, and I look forward to contributing to the advancement of Marker's clinical programs and long-term growth.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4142","IE00BD0PCF45.HKD","BK4585","MRKR","BK4588","IE00B45NX917.SGD","IE00B95QR487.USD","IE00B0T0GQ85.USD","IE00B1G9WX41.USD","MAR","BK4007","LU1718418525.SGD","BK4539","BK4139","LENZ"],"gpt_icon":0},{"id":"2581677747","title":"Marker Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Kathryn Penkus Corzo","url":"https://stock-news.laohu8.com/highlight/detail?id=2581677747","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581677747?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:55","pubTimestamp":1762293314,"startTime":"0","endTime":"0","summary":"Marker Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Kathryn Penkus Corzo as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL9byRsQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRKR","BK4139"],"gpt_icon":0},{"id":"2573671050","title":"Marker Therapeutics announces first patient treated in off-the-shelf program","url":"https://stock-news.laohu8.com/highlight/detail?id=2573671050","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573671050?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:40","pubTimestamp":1759750846,"startTime":"0","endTime":"0","summary":"Marker Therapeutics (MRKR) announced that the first patient has been treated in the Company’s OTS program, with encouraging preliminary safety data...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/marker-therapeutics-announces-first-patient-treated-in-off-the-shelf-program-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/marker-therapeutics-announces-first-patient-treated-in-off-the-shelf-program-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","MRKR","BK4539","BK4007"],"gpt_icon":0},{"id":"2573671169","title":"Marker Therapeutics Launches Phase 1 Clinical Trial of Off-the-Shelf MAR-T Cell Therapy, Treats First Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2573671169","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573671169?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:31","pubTimestamp":1759750276,"startTime":"0","endTime":"0","summary":"Marker Therapeutics Inc. , a clinical-stage immuno-oncology company, announced the initiation of its Phase 1 RAPID study to investigate its Multi-Antigen Recognizing  T cells as an Off-the-Shelf  product for the treatment of hematological malignancies and solid tumors. The company has treated the first patient in this program and reported encouraging preliminary safety data, indicating that the OTS product was well tolerated, with safety outcomes consistent with previous MAR-T cell studies. Marker Therapeutics stated that the OTS approach aims to accelerate time to treatment and improve scalability by utilizing leukapheresis material from healthy donors. Further results from the ongoing trial will be collected and analyzed as additional patients are enrolled. The company has received non-dilutive funding from the FDA, NIH SBIR program, and the Cancer Prevention and Research Institute of Texas to support the clinical investigation of the OTS product.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL2qf9S0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRKR","BK4139"],"gpt_icon":0},{"id":"2562758479","title":"BUZZ-U.S. STOCKS ON THE MOVE-Trump Media, Gold miners, Cracker Barrel","url":"https://stock-news.laohu8.com/highlight/detail?id=2562758479","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562758479?lang=en_us&edition=fundamental","pubTime":"2025-08-26 23:40","pubTimestamp":1756222810,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Trump Media, Gold miners, Cracker BarrelEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nL6N3UI0MN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1978683503.SGD","WORX","LU0130103400.USD","MRKR","LU2491050154.USD","LU2552382215.SGD","GNRC","LU1582986359.USD","IBRX","LU1852331112.SGD","UP","CBRL","GEV","DVN","NEM","T","SST","DQ","GCO","EXR","CPT","AU","CVX","DJT","TRUMP.USD.CC","CTRN","WBA","XOM","WOLF","FEMY","BTCM","EPIX","TLN","KNTK","UUUU","PACK","STZ","YMAT","FANG","KDP","ALLR","SATS","IBKR","BAC"],"gpt_icon":1},{"id":"2562120733","title":"BUZZ-Marker Therapeutics jumps after blood cancer trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2562120733","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562120733?lang=en_us&edition=fundamental","pubTime":"2025-08-26 19:46","pubTimestamp":1756208780,"startTime":"0","endTime":"0","summary":"BUZZ-Marker Therapeutics jumps after blood cancer trial data** Shares of drug developer Marker Therapeutics MRKR.O up 29% at $1.63 premarket** Co reports data from its ongoing early-stage trial testing its experimental therapy, MT-601, in patients with relapsed B-cell lymphoma, a type of blood cancer that has returned after previous treatment** Co says 66% of patients saw their cancer shrink or disappear, with 50% showing no detectable cancer after treatment** The therapy had no severe side effects, co says** As of last close, stock down 60% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nL4N3UI0VB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRKR","BK4139"],"gpt_icon":0},{"id":"2562738427","title":"Marker Therapeutics Inc. Unveils Presentation on MAR-T Cell Platform and Lead Product MT-601 for Tumor Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2562738427","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562738427?lang=en_us&edition=fundamental","pubTime":"2025-08-26 19:24","pubTimestamp":1756207452,"startTime":"0","endTime":"0","summary":"Marker Therapeutics Inc., listed on NASDAQ as MRKR, has unveiled its latest corporate presentation highlighting the advancements in its MAR-T Cell Platform technology. Developed at Baylor College of Medicine, the MAR-T  technology offers potential therapeutic and manufacturing benefits over traditional T cell therapies. Marker's lead product, MT-601, targets six tumor-specific antigens, positioning it for broad tumor recognition and treatment. The MT-601 has demonstrated durable objective response rates in a Phase 1 clinical trial for lymphoma patients who have relapsed after anti-CD19 CAR-T cell therapy or for whom CAR-T cell therapy is not viable. The company maintains a robust intellectual property position with FDA-cleared investigational new drug applications for three MAR-T based clinical programs. Marker Therapeutics continues to seek non-dilutive funding, having secured over $30 million to date. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nNDLVzx50:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRKR","BK4139"],"gpt_icon":0},{"id":"2562269780","title":"Marker Therapeutics Inc - Mt-601 Infusion Well Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2562269780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562269780?lang=en_us&edition=fundamental","pubTime":"2025-08-26 19:00","pubTimestamp":1756206024,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nTUA5RVRDT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MRKR"],"gpt_icon":0},{"id":"2562119780","title":"Marker Therapeutics Inc - No Dose Limiting Toxicities or Icans Observed","url":"https://stock-news.laohu8.com/highlight/detail?id=2562119780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562119780?lang=en_us&edition=fundamental","pubTime":"2025-08-26 19:00","pubTimestamp":1756206024,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nTUA5RVRDT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRKR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.markertherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1333},{"period":"1month","weight":-0.2143},{"period":"3month","weight":0.5493},{"period":"6month","weight":0.1349},{"period":"1year","weight":-0.1588},{"period":"ytd","weight":-0.0403}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.055182},{"month":2,"riseRate":0.3,"avgChangeRate":-0.079409},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.080323},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.002513},{"month":5,"riseRate":0.555556,"avgChangeRate":0.241279},{"month":6,"riseRate":0.555556,"avgChangeRate":0.258108},{"month":7,"riseRate":0.111111,"avgChangeRate":-0.078392},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.035761},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.06731},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.021955},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.047609},{"month":12,"riseRate":0.3,"avgChangeRate":0.054056}],"exchange":"NASDAQ","name":"Marker Therapeutics, Inc.","nameEN":"Marker Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Marker Therapeutics, Inc.(MRKR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Marker Therapeutics, Inc.(MRKR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Marker Therapeutics, Inc.,MRKR,Marker Therapeutics, Inc.股票,Marker Therapeutics, Inc.股票老虎,Marker Therapeutics, Inc.股票老虎国际,Marker Therapeutics, Inc.行情,Marker Therapeutics, Inc.股票行情,Marker Therapeutics, Inc.股价,Marker Therapeutics, Inc.股市,Marker Therapeutics, Inc.股票价格,Marker Therapeutics, Inc.股票交易,Marker Therapeutics, Inc.股票购买,Marker Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Marker Therapeutics, Inc.(MRKR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Marker Therapeutics, Inc.(MRKR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction